Kane Biotech Study Links Revyve Wound Gel to 43.9% Mean Wound Area Reduction

• Kane Biotech announced published results in the International Wound Journal evaluating revyve Antimicrobial Wound Gel alongside standard wound care.
• The prospective observational study followed 17 adults with 28 chronic and complex wounds for up to 12 weeks.
• Adjunctive treatment was associated with reduced wound size, improved wound bed condition and lower patient-reported pain.
• All wounds had failed prior treatment; median wound duration before treatment was 22 months.
• The authors called for larger, controlled studies; revyve has FDA 510(k) clearance and a Health Canada license.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040705PRIMZONEFULLFEED9869570) on November 04, 2026, and is solely responsible for the information contained therein.